PBA
CMPS

Paradigm Biocapital Advisors’s Compass Pathways CMPS Stock Holding History

Paradigm Biocapital Advisors’s Portfolio CMPS Stock Details CMPS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,160,000
Closed -$7.31M – 33
2024
Q3 		$7.31M Sell
1,160,000
-1,175,926
-50% -$8.3M 0.25% 33
2024
Q2 		$14.1M Sell
2,335,926
-55,062
-2% -$433K 0.54% 28
2024
Q1 		$19.9M Buy
2,390,988
+125,000
+6% +$1.26M 0.7% 28
2023
Q4 		$19.8M Buy
2,265,988
+907,279
+67% +$5.87M 0.93% 23
2023
Q3 		$10.1M Buy
+1,358,709
New +$12M 0.68% 28

Other funds holding CMPS

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Paradigm Biocapital Advisors's CMPS Position: Q4 2024 in Review

Paradigm Biocapital Advisors sold out of Compass Pathways (CMPS) in Q4 2024, closing a stake of 1,160,000 shares — an estimated $7.31M sold.

Paradigm Biocapital Advisors first reported a position in CMPS in Q3 2023 and held it in 5 quarters. The position peaked at $19.9M in Q1 2024. 132 funds tracked by Wall St. Rank hold CMPS as of Q4 2024.

  • Paradigm Biocapital Advisors reported no remaining Compass Pathways position as of Q4 2024 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 1,160,000 Compass Pathways shares in Q4 2024, an estimated $7.31M.
  • Paradigm Biocapital Advisors first reported a position in Compass Pathways in Q3 2023 and held it in 5 quarters.
  • Paradigm Biocapital Advisors's Compass Pathways position peaked at $19.9M in Q1 2024.
  • 132 funds tracked by Wall St. Rank held Compass Pathways as of Q4 2024.

Based on Paradigm Biocapital Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.